Showing results (181-190 of 200) with videos related to
Sort By:
Pageof 20
Science (New York, N.Y.)|May 21, 2016
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1Till Schoofs, Florian Klein, Malte Braunschweig, et al.The Journal of Experimental Medicine|August 4, 2018
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117Yehuda Z Cohen, Julio C C Lorenzi, Lisa Krassnig, et al.Biorxiv : the Preprint Server for Biology|August 4, 2020
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variantsYiska Weisblum, Fabian Schmidt, Fengwen Zhang, et al.The Lancet. Microbe|May 11, 2022
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trialHenning Gruell, Jesper D Gunst, Yehuda Z Cohen, et al.Nature|April 10, 2015
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117Marina Caskey, Florian Klein, Julio C C Lorenzi, et al.Biorxiv : the Preprint Server for Biology|March 24, 2021
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodiesFrauke Muecksch, Yiska Weisblum, Christopher O Barnes, et al.Immunity|July 31, 2021
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutationsFrauke Muecksch, Yiska Weisblum, Christopher O Barnes, et al.Plos One|August 9, 2019
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 studyYehuda Z Cohen, Allison L Butler, Katrina Millard, et al.Plos Pathogens|July 6, 2021
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaquesKoen K A Van Rompay, Katherine J Olstad, Rebecca L Sammak, et al.Nature|June 25, 2016
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionJohannes F Scheid, Joshua A Horwitz, Yotam Bar-On, et al.Pageof 20